Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3805
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines.

    To find out more about Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
3SBio
AB Science
Abbott
AbbVie
Abiogen
AC Immune
Access
Actelion
Adaptimmune
Adherex
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apotex
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celera
Celgene
Celldex Therapeutics
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chlorogen
Chroma Therapeutics
CJ Corp
Clavis Pharma
Cleveland BioLabs
CombinatoRx
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CSL
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DNAVEC
Dong-A
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Etubics
Exelixis
Flamel Technologies
Galena Biopharma
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Gerolymatos
Geron
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Glycotope
GPC Biotech
Gradalis
Green Cross
Harbor BioSciences
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intradigm
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Momotaro-Gene
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novelix
Novogen
Oasmia
Oncalis
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Pharminox
PhiloGene
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protherics
QLT
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regulon
Reliance Life Sciences
responsif
Rexahn
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
SBI Biotech
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Shionogi
Shire
Sigma-Tau
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spirogen
SRI International
Sunesis
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synta Pharmaceuticals
Takeda
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Tigris Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
UMN Pharma
United Biomedical
Vaccinex
ValiRx
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
VioQuest
Viragen
Viralytics
Virionics
ViroMed
ViroTarg
VM Discovery
WntResearch
Xerion
York Pharma
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
ADXS11-001
AE-37
AEB071
AEG-35156
agatolimod
AGS-003
aldesleukin
ALT-801
alvocidib
AME-133
ANZ-207
APG-101
APO-866
ARQ-197
ARRY-438162
AS-101
AS-1411
astuprotimut-r
Auto TAG vaccine
AVX-701
axitinib
bardoxolone methyl
belagenpumatucel-L
belinostat
bevacizumab
BMS-663513
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
Buparlisib
BV-NSCLC-001
BZL-101
Cabozantinib
canfosfamide hydrochloride
CB-10-01
CDX-1307
cenersen
CG-201
cilengitide
cintredekin besudotox
conatumumab
cositecan
CreaVax-PC
crolibulin
CT-011
CV-9103
CV-9201
CVac
dasatinib
DCVax-prostate
decitabine
denenicokin
denileukin diftitox
dinaciclib
dovitinib lactate
dulanermin
E-75
E7449
EMD-273063
emepepimut-S
endostatin
entinostat
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
fosbretabulin tromethamine
fresolimumab
ganetespib
ganitumab
gataparsen
gefitinib
GI-4000
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
HE-3235
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
HS-110
ibritumomab tiuxetan
ICT-107
idronoxil
imatinib mesilate
imetelstat
imMucin
IMO-2055
INCB-24360
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
LEE-011
lenvatinib
lestaurtinib
LGX818
LipoVIL12
litronesib
lonaprisan
lumiliximab
mapatumumab
MDX-1379
MetXia
MGN-1601
MKC-1
MKC-1106-MT
mocetinostat
MORAb-004
motexafin gadolinium
MVA-BN Her-2 vaccine
navitoclax
nilotinib
noscapine
obinutuzumab
oblimersen sodium
ON-01910
Oncohist
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
panobinostat
PAT-SC1
PBI-1402
PCI-24781
peginterferon alfa-2b
perifosine
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
retaspimycin
Reximmune-C
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
S-488410
sagopilone
sargramostim
SCIB-1
seliciclib
selumetinib
sipuleucel-T
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Survivac
talminogene laherparepvec
terameprocol
tesetaxel
TG-4010
thalidomide
thymalfasin
tigapotide triflutate
tigatuzumab
tipapkinogene sovacivec
tipifarnib
TL-32711
trabedersen
tremelimumab
triciribine phosphate
TroVax
TRU-016
velimogene aliplasmid
veliparib
vemurafenib
verpasep caltespen
verubulin
vinflunine ditartrate
vitespen
volasertib
volociximab
vosaroxin
VX-001
XL-147
XL-647
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines.
    To find out more about Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Apoptosis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Lymphoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Melanoma, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More